Kearney, NE., - SCORR Marketing, a global health science marketing and communications firm, in association with Applied Clinical Trials, has released the results of a comprehensive survey on the use of paperless processes in clinical trials. The report describes which paperless processes have largely been implemented and the biggest benefits that have been realized. It also pinpoints which stakeholders are most reluctant to implement paper processes and forecasts what the future holds for these processes. “In the survey, we discovered that the users of paperless processes felt strongly that these processes have improved data collection as well as data and document quality,” said Cliff Echols, director of market intelligence at SCORR. “However, some users, particularly those from academic institutions, report that paperless processes haven’t reduced the need for data entry as much as they had hoped.” The survey also gathered information on current levels of paperless data collection, the benefits and challenges stemming from eClinical processes, resistance and hurdles concerning paperless trials and predictions about the future of the practice. Respondents included individuals from across the globe, representing CROs, pharmaceutical companies, academic institutions, consultancies, service providers, research sites, hospitals and medical device companies. “We found that the cost of technology and fear of change were the two greatest hindrances to the adoption of paperless processes,” said Lisa Henderson, editor in chief at Applied Clinical Trials, a part of the life sciences unit of UBM. “However, many respondents, particularly those working within a CRO, believe that there will still be a dramatic increase in their company’s use of paperless processes over the next three years.” Download the full report at scorrmarketing.com. About SCORR Marketing SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.